THAILAND EPI VACCINE

BIRTH: BCG, HB. VAC. 1
2 mo.: DTP, OPV, HB. VAC. 2
4 mo.: DTP, OPV
6 mo.: DTP, OPV, HB. VAC. 3
9-12 mo.: Measles or MMR
18 mo.: DTP, OPV
The HB vaccine coverage as part of Thailand’s EPI

![Bar graph showing vaccine coverage before and after EPI]
Hepatitis B virus markers in children under 18 years. 1999

Percent

Before EPI

After EPI

HBsAg
antiHBc
antiHBs

Month

Vaccine 2001
### Impact of universal Hepatitis B immunisation 1999

<table>
<thead>
<tr>
<th>Country</th>
<th>Age Group (Years)</th>
<th>Before universal</th>
<th>After universal</th>
</tr>
</thead>
<tbody>
<tr>
<td>Taiwan (1984)</td>
<td>&gt;15-20 Yr</td>
<td>7 %</td>
<td>0.7 %</td>
</tr>
<tr>
<td></td>
<td>&lt;15 Yr</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Thailand (1989-1992)</td>
<td>≥10-18 Yr</td>
<td>3.4 %</td>
<td>0.7 %</td>
</tr>
<tr>
<td></td>
<td>&lt;10 Yr</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Poovorawan et al. Vaccine 2001
 GMT evolution 0, 1, 2, 12 months

Cohort 1: booster + HB Ig  Cohort 2: booster no HB Ig  Cohort 3: no booster no HB Ig

Atlanta, 2000 Congress
Seropositivity rates 0, 1, 2, 12 months

Cohort 1: booster + HBlg  Cohort 2: booster no HBlg  Cohort 3: no booster no HBlg

Atlanta, 2000 Congress
High Protective Efficacy in Neonates with or without HBlg

Protective efficacy at 1 year (%)

- 0, 1, 6 month regimen
  - Without HBlg: 92.3%
  - With HBlg: 100%

- 0, 1, 2, 12 month regimen
  - Without HBlg: 94.8%
  - With HBlg: 97.6%

HB vaccine, 10 mcg/dose (SB vaccine)

Poovorawan, Y et al. 1989; Pediatr Infect Dis J. 1992